FDA about these proceedings. However, FDA will refrain from discussing the details of
this meeting with the media until its conclusion. A press conference will be held in the
Sovereign Room immediately following the meting today. Also the committee is
reminded to please refrain from discussing the meeting topic during breaks or lunch.
meeting, there are often a variety of opinions, some of which are quite strongly held. Our
goal is that today’s meeting will be a fair and open forum for discussion of these issues
and individuals can express his/her views without interruption. Thus, as a gentle
reminder, individuals will be allowed to speak into the record only if recognized by the
Chair. We look forward to a productive meeting.
Endocrinologic and Metabolic Drugs Advisory Committee under the authority of the
Federal Advisory Committee Act of 1972. With the exception of the industry
representative, all members and temporary voting members are Special Government
Employees (SGEs) or regular Federal employees from other Agencies and are subject to
Federal conflict of interest laws and regulations.
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
in the Sunshine Act, we ask that the Advisory Committee members take care that their
conversations about the topic at hand take place in the open forum of the meeting.
CONFLICT OF INTEREST STATEMENT
PAUL TRAN, R.PH.
DR. BURMAN: For a topic, such as those being discussed at today’s
In the spirit of the Federal Advisory Committee Act and The Government
We are aware that members of the media are anxious to speak with the